about
Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program.Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.Antibiotic restriction policy paradoxically increased private drug consumptions outside Taiwan's National Health Insurance.Bacteremia due to Acinetobacter genomic species 10.Sheltering effect and indirect pathogenesis of carbapenem-resistant Acinetobacter baumannii in polymicrobial infection.Levofloxacin-resistant haemophilus influenzae, Taiwan, 2004-2010.Comparison of microbiological and clinical characteristics based on SCCmec typing in patients with community-onset meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia.Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in TaiwanDeterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritisComparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialisIncidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study.Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii.A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii.Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma.Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii.Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm ArchitectureAcinetobacter baumannii Extracellular OXA-58 Is Primarily and Selectively Released via Outer Membrane Vesicles after Sec-Dependent Periplasmic Translocation.Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case-control study.Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.Effect of the use of low and high potency statins and sepsis outcomes.Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study.In vitro activity of SecA inhibitors in combination with carbapenems against carbapenem-hydrolysing class D β-lactamase-producing Acinetobacter baumannii.Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.Risk of Mortality of Catheter-Related Bloodstream Infections Caused by Acinetobacter Species.Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.Sensitivity and specificity of Matrix-Associated Laser Desorption/Ionization - Time of Flight Mass Spectrometry (MALDI-TOF MS) in discrimination at species level for Acinetobacter bacteremia.Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.Molecular epidemiology of carbapenem non-susceptible Acinetobacter nosocomialis in a medical center in Taiwan.Long-Term Mortality and Major Adverse Cardiovascular Events in Sepsis Survivors. A Nationwide Population-based Study.Long-Term Outcomes in Critically Ill Septic Patients Who Survived Cardiopulmonary Resuscitation.Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort.Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus.A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate.Effective transfer of a 47 kb NDM-1-positive plasmid among Acinetobacter species.Comparison between bacteremia caused by Acinetobacter pittii and Acinetobacter nosocomialis.Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study.Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis.
P50
Q30559669-73659349-1111-4DF8-9031-F658BA8BEF83Q31131682-F1DF2F16-5582-438B-A28F-806F07DA3542Q33589772-32DBAE26-6481-4FC9-B26D-CB24035A09CEQ33627416-F0288E14-CC72-43D2-82CB-54D414EA4682Q33798228-28264378-257E-422A-ADD1-02591EAA0EFCQ33951148-C8EEEFD5-8523-4917-83B5-5553902EE2DEQ34222462-FEF790F4-EF03-45FF-A479-68A953D138D1Q34290153-42A18446-E58D-4A34-B0E3-D880473C371EQ34534575-035C1344-1388-4C0F-85CF-9B7DBA1E1755Q34809946-2A124925-E7F3-4D93-893D-AD3123CBDE34Q34878535-B30E9B03-437B-4296-A49E-67E2943C9E45Q35607639-67C6A6F6-6203-4860-8808-1F51247E5EE2Q35689254-A4BA2F97-7892-4658-AFDF-AF4251D861C5Q35794129-44F8C066-23B9-4288-9FF3-67EBA8F6EC29Q35809324-476E58C3-F595-4D3A-AD8C-A2BD42528CFDQ35895209-E96C06DD-B499-421C-B131-BFC8034859D1Q36027243-16347058-0014-4327-BB3F-41FC996AABC4Q36290822-689D621E-404B-4EAE-AC1A-15F249C99DB1Q36293975-8F012AC8-4B40-4DC6-92C1-4D75EAAEDE54Q36905430-912C4B90-D224-44DF-BCA4-CD2683286475Q37023110-30D342F4-A497-4C94-893B-8850970FDD4BQ38236894-227CF915-34C5-4E56-A19F-1A766307C1FBQ38941330-CF716CD8-E313-49EA-9E97-FA7C5834FBC0Q38945089-61801321-18D0-42B6-84E6-8A36C5E47496Q38973363-C8606F98-B913-410F-A04F-3CEA2D761445Q39167614-64F9BBB3-FD3B-4A6B-9ED3-C60F83B42024Q39167693-E82C0762-10F0-4997-B534-BEA0989FEEABQ39372676-93667229-B87B-4053-80F4-2F7B91DF0B59Q39605144-915E1398-9C9B-469E-89A9-CE8252C9E462Q39613942-2DC3AC51-B7EB-44D5-B8E2-C7BE0A8B3F3CQ39613951-4C746A1C-4A56-4C4C-9848-CB3E6E8354B9Q40063876-C354F132-88D3-4356-9B65-B3955D5FAF3AQ40065234-8E9F9A62-B58A-41A2-96BB-C7CDF3A47A26Q40198790-4595CE2D-78F2-46E4-9D3C-68C0282926D0Q40268100-1B6FF0BC-5D63-455D-96E1-40003D20D7B4Q40335432-44E8E204-D896-43D7-BC94-EEF8229EB001Q41105851-933D89C2-680E-4C1B-B44E-6CA1F41F0751Q41452837-D0E60ABC-70ED-46B6-B9FA-F5AEFE323D13Q41738550-18A9BC0B-CDA3-4EF6-9FB5-3C7C180D1644Q41743549-5B735AB6-92D8-4E9F-8CC2-96A517B6E46C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shu-Chen Kuo
@ast
Shu-Chen Kuo
@en
Shu-Chen Kuo
@es
Shu-Chen Kuo
@nl
type
label
Shu-Chen Kuo
@ast
Shu-Chen Kuo
@en
Shu-Chen Kuo
@es
Shu-Chen Kuo
@nl
prefLabel
Shu-Chen Kuo
@ast
Shu-Chen Kuo
@en
Shu-Chen Kuo
@es
Shu-Chen Kuo
@nl
P106
P31
P496
0000-0002-6940-6450